Abstracts tagged "auto-immunity and interferons"

Abstract Number: 3025 • 2015 ACR/ARHP Annual Meeting
FcγRIIIa-Psyk Signaling up-Regulates TLR3 and TLR5 in Human Naïve CD4+ T-Cells
Chen Chen¹, Ye Bi², Terry Moore³ and Anil K. Chauhan⁴, ¹Rheumatology/Internal Medicine, Saint Louis University, St. Louis, MO, ²Internal Medicine, Saint Louis University, St. Louis, MO, ³Division of Rheumatology and Pediatric Rheumatology, Saint Louis University School of Medicine, St Louis, MO, ⁴Internal Medicine-Rheumatology, Saint Louis University, St Louis, MO
Background/Purpose: To delineate mechanism of FcγRIIIa-pSyk signal in TH17 and IFN-γhigh subset development. To examine whether Toll-like receptor signaling play a role in CD4+ T-cell…
Abstract Number: 2172 • 2014 ACR/ARHP Annual Meeting
PTPN22 Promotes TLR-Induced Amelioration of Arthritis
David Ewart¹, Erik J. Peterson¹ and Yaya Wang², ¹University of Minnesota, Minneapolis, MN, ²Center for Immunology, University of Minnesota, Minneapolis, MN
Background/Purpose: Rheumatoid arthritis (RA) synovial fluid exhibits high levels of type 1 interferons (IFN). Type 1 IFN may exert potent anti-inflammatory effects, since a TLR3…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].